Primary Oesophageal Involvement by Non-Hodgkin Lymphoma: A case report and a literature review

Esophageal involvement in non-Hodgkin lymphoma (NHL) is uncommon and generally secondary to disseminated disease. Primary esophageal NHL is extremely rare, with only a few cases reported in the literature. We conducted a systematic review of the PubMed and Google Scholar medical databases and identified 38 cases of primary esophageal diffuse large B-cell lymphoma (DLBCL). The majority of the patients were male, with a median age of 60 years. Progressive dysphagia was the primary symptom. The ituximab, cyclophosphamide, oncovin, and vincristine (RCHOP) regimen is the mainstay of treatment. We report an additional case of primary esophageal DLBCL, highlighting the challenging diagnosis and therapeutic management of this uncommon presentation.

Authors

Institutions

Publication Details

Journal
F1000Research
Published
2026-10-28
DOI
https://doi.org/10.12688/f1000research.191447.1
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Primary Oesophageal Involvement by Non-Hodgkin Lymphoma: A case report and a literature review

Sabrine Boukhris, Karima Kacem, Hana Ben Hammamia, Najet Mahjoub et al.
F1000Research
Lymphoma Diagnosis and Treatment
article

Primary Oesophageal Involvement by Non-Hodgkin Lymphoma: A case report and a literature review

Sabrine Boukhris, Karima Kacem, Hana Ben Hammamia, Najet Mahjoub, Sayadi malek
article en

Abstract

Esophageal involvement in non-Hodgkin lymphoma (NHL) is uncommon and generally secondary to disseminated disease. Primary esophageal NHL is extremely rare, with only a few cases reported in the literature. We conducted a systematic review of the PubMed and Google Scholar medical databases and identified 38 cases of primary esophageal diffuse large B-cell lymphoma (DLBCL). The majority of the patients were male, with a median age of 60 years. Progressive dysphagia was the primary symptom. The ituximab, cyclophosphamide, oncovin, and vincristine (RCHOP) regimen is the mainstay of treatment. We report an additional case of primary esophageal DLBCL, highlighting the challenging diagnosis and therapeutic management of this uncommon presentation.

F1000ResearchVol. 15
Faculté de médecine de Tunis (TN), Tunis El Manar University (TN)
Good health and well-being
Openalex Percentile: Top 12%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon